论文部分内容阅读
癌胚抗原(CEA)检测胃癌的特异性不高,CA19-9的敏感性变异很大,可在15%～72%之间,联合测定CEA和CA19-9也不提高其敏感性.近期发现一种新的肿瘤相关糖蛋白抗原TAG-72,可在胃肠道腺癌病人的血清中检出,现用的药盒用CA72-4分析,应用单克隆抗体B72.3和CC49的双重决定因子免疫分析法.初步报告CA72-4是胃癌的可靠肿瘤标记物,并可补充CA19-9测定的效果.取32例经内镜和病理证实的胃良性病变和52例经手术切除的胃腺癌病人进行测定,两组病人的中位值年龄分别为36岁和61岁.胃癌病人中,属TNMⅠ、Ⅱ、Ⅲ和Ⅳ期分别占7、5、11和29例.结果凡CA72-4和CA19-9的血清值分别超过6.7kU/L和22kU/L者列为阳性结果.在32例良性胃病变中,CA72-4和CA19-9的阳性率分别为0和28%;而在52例胃癌病人中,则分别为42%和46%,这两种肿瘤标记物具有相似的敏感性,但CA19-9的特异性较低.进一步分析示良性病变者的CA19-9血清值变异较CA72-4为大.在Ⅰ、Ⅱ期和Ⅲ、Ⅳ期胃癌中,CA72-4的阳性率分别达25%和48%,CA19-9的阳性率分别为17%和55%,
The specificity of carcinoembryonic antigen (CEA) in the detection of gastric cancer is not high, and the sensitivity of CA19-9 varies greatly, ranging from 15% to 72%. Joint determination of CEA and CA19-9 does not increase its sensitivity. A new tumor-associated glycoprotein antigen, TAG-72, can be detected in the serum of patients with gastrointestinal adenocarcinoma. The current kit is analyzed with CA72-4 and the dual determination of monoclonal antibody B72.3 and CC49 is used. Factor immunoassay. Preliminary report CA72-4 is a reliable tumor marker for gastric cancer and can complement the effect of CA19-9 assay. 32 cases of endoscopic and pathologically confirmed benign gastric lesions and 52 cases of surgically resected gastric adenocarcinoma Patients were measured and the median age of the two groups of patients was 36 years and 61 years, respectively. In patients with gastric cancer, TNMI, II, III, and IV stages accounted for 7, 5, 11 and 29 cases respectively. Results where CA72-4 and The serum levels of CA19-9 were more than 6.7 kU/L and 22 kU/L, respectively. The positive rates of CA72-4 and CA19-9 in 32 cases of benign gastric lesions were 0 and 28%, respectively. In patients with gastric cancer, they were 42% and 46%, respectively. These two tumor markers have similar sensitivities, but the specificity of CA19-9 is lower. Further analysis of CA19-9 blood showed benign lesions. The clear value variation was greater than that of CA72-4. The positive rate of CA72-4 in stage I, II and III, IV gastric cancer was 25% and 48%, respectively, and the positive rate of CA19-9 was 17% and 55%, respectively. ,